Vacancy: Data manager clinical genetic breast cancer project

This vacancy has been proposed by the Antoni van Leeuwenhoek.

Testing and counseling for breast cancer heritability in clinical genetics is about to change with the development and applicability of polygenic risk scores. This requires further research in collaboration with all clinical genetics centres in the Netherlands. KWF finances us to make this possible through an infrastructure project (Hebon-infra). This will make data on hereditary variants, family history, lifestyle, breast density and clinical information accessible to researchers. A new prospective cohort will be set up at the same time.

Your function
You will have a lead role in managing the databases in our project (e.g. the questionnaire data on risk factors). You will help create and harmonize new databases related to family history and mammography data. You will also be responsible for cleaning the data, documenting, and building new questionnaires in Microsoft InfoPath.

You will work closely with an enthusiastic project team, including a project leader, project coordinator, and central data manager. You will further collaborate with local data managers, ICT staff, clinical geneticists, epidemiologists, oncologists, organisations in ICT and with all teaching hospitals. Good communication skills and a proactive attitude are absolutely essential. Being able to work carefully and precisely as well.

More information about the Hebon project
Hebon (Hereditary Breast and Ovarian Cancer Research in the Netherlands) is a collaboration between all Clinical Genetic Centres in the Netherlands and the Antoni van Leeuwenhoek hospital. Internationally, Hebon is actively involved in the following collaborations: IBCCS (International BRCA1/2 carrier cohort study), CIMBA (Consortium of Investigators of Modifiers of BRCA1/2), BCAC (Breast Cancer Association Consortium) and ENIGMA (Genetic variants in BRCA1/2) Consortia.

Women with an increased risk of breast or ovarian cancer can be tested at one of the University Medical Centers or the Antoni van Leeuwenhoek for a germline mutation in, among others BRCA1, BRCA2, CHEK2, ATM, PALB2. Currently, from the genetic test result and detailed family history, the future risk of breast and ovarian cancer is estimated. This risk assessment is leading for the advice on screening and prevention. Recent developments make it possible to tailor risk estimation to a higher extent by basing it not only on the mutation test and the family history, but also on a polygenic risk score (based on multiple single nucleotide polymorphisms), on known hormonal/lifestyle factors and on breast density. In this way, not only members of mutation families, who are often confronted with very difficult choices concerning preventive measures, but also members of families in which no mutation is found (approx. 90%), can be better advised. Our national prospective Hebon cohort study has actively contributed to these recent developments. The current project is an important step to start implementing the new personalized risk prediction in the clinic. In addition, Hebon wants to be well equipped for the future to evaluate and improve the updated risk estimate and continue to conduct other relevant research on behalf of families with high incidence of breast and ovarian cancer. Therefore, in the coming years we will build an infrastructure through which the research population will be routinely invited and the necessary (clinical) research data can be collected. The cleaning of the data will also undergo an automation process. In addition, the harmonisation and cleaning of international data will be part of this infrastructure.

Your profile

You have preferably completed an academic education with background in epidemiology, health sciences or similar.
You are energetic, an initiator, decisive, a go-getter and you want to take on several parts of the project.
You have experience in cleaning and harmonizing large data files.
You have experience working in Microsoft Access and/or SQL, InfoPath, R, STATA or SPSS.
You have good communication skills, both verbal and written.

Your development opportunities and employment conditions
This is an employment contract for a period of 3 years. Depending on your educational level and work experience, the salary amounts to a minimum of € 2.526 and a maximum of € 3.774 gross per month based on a 36-hour work week, in accordance with FWG 50 of the CAO ziekenhuizen.

In addition, 8.33% holiday pay and a fixed year-end bonus are part of our terms of employment. You will receive a travel allowance of € 0.08 per km, which can be supplemented to € 0.19 per km at the end of the year through our More Choices employment conditions scheme.

As an employee of Antoni van Leeuwenhoek you can park for free. Of course we encourage our employees to leave their car at home, so we offer an interesting bicycle scheme and/or discount on an NS (Dutch railways) business card. As an employer we contribute 50% to your pension at Pensioenfonds Zorg & Welzijn and we offer a group discount for the healthcare insurers IZZ and Zilveren Kruis and disability insurance.

Contact information
For further information, please visit our website (
www.hebon.nl
) or contact Rosa de Groot (project coordinator), e-mail: ro.d.groot@nki.nl [email protected] or telephone number 020-512 6137 and/or Marjanka Schmidt (project manager), e-mail:
mk.schmidt@nki.nl
[email protected] or telephone number: 020-512 2767.

Apply now?
You can add your application letter and curriculum vitae as attachments to the web form (
Click on this link
), at the latest on Wednesday 10-11-2021. After submitting the form you will soon receive a response from us.

The first round of interviews will take place on Monday, November 18, 2021, and the second round will take place on Thursday, December 2, 2021.

Only if the above web form cannot be filled in due to unexpected technical reasons, you can respond via recruitment@nki.nl mentioning the vacancy title in the subject line of the e-mail.

Acquisition in response to this vacancy is not appreciated.

Date of entry: 28 October 2021